MARKET WIREYahoo Finance • 21h ago
Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 EarningsYahoo Finance report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
Why CNMD Stock surged +5.19% Today — RQD Quant Desk Flash
$46.59 +5.19% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $46.94
CONMED Corporation (CNMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $1.32B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CNMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CNMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, CONMED Corporation (NYSE: CNMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $46.59 (+5.19% 1D, market cap $1.32B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, CNMD ranks #149 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CNMD compare to CBLL and TMDX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CNMD carries a Roarable C (62/100 RQD), trailing P/E of 28.9x, gross margin of 54.6%, and ROIC of 7.8%. By comparison, CBLL (CeriBell Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and TMDX (TransMedics Group Inc.) posts a C- grade (61/100 RQD, P/E 12.2x, ROIC 18.1%, cap $2.29B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CNMD?
▼
Per CNMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000816956), CONMED Corporation generated $1.37B in revenue (+5.2% YoY), $47.1M in net income, and $150.9M in free cash flow against $2.33B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $46.93 (+0.74%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 11% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNMD)Realized 20D OHLCV Swing Band: ±8.4%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY CNMD SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (23% of score)
Altman Z-Score 1.91 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$45.55+4.5% Next Q
54
Q2 (-2Q)Grade C$47.58-0.8% Next Q
57
Q3 (-1Q)Grade C$47.20-1.3% Next Q
59
CurrentGrade C$46.59+0.7% Hist 90D α
62
Trajectory: C- (54) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CNMD Bull Thesis Could Fail
Even with a 62/100 (C) score, CNMD faces multiple-compression risk if 28.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 52.1% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($46.82) or 200D SMA ($41.44) invalidates the momentum regime and cuts Target Base ($47.43) toward Bear Floor ($37.00).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CNMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CNMD Stock surged +5.19% Today — RQD Quant Desk Flash
CONMED Corporation (CNMD) surged +5.19% to $46.59, trading at 68% of its 52-week range ($31.44 – $53.66). Solid 54.6% gross margin (8% return on capital), mixed timing at 29x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 68% of its 52-week range ($31.44 – $53.66) with RSI-14 at 42.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.4% around $46.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 54.6% gross margin and $150.9M annual free cash flow.
Live CNMD Headlines & Catalysts
CATALYSTTradingView • 1d ago
CONMED Corporation Stock 12‑Month Price Target Raised to $46.83, Implies 2% UpsideTradingView report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
CONMED Corporation 2026 Q3 - Results - Earnings Call Presentation (NYSE:CNMD) 2026-11-01Seeking Alpha report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
CONMED (NYSE:CNMD) - Stock AnalysisSimply Wall St report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
CONMED Corporation (CNMD) Stock ForecastsYahoo Finance report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Sales fell 0.7%, but grew 6.7% after currency shifts and exited product lines were excluded.Stock Titan report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
CONMED Corporation $CNMD Stake Reduced by Cooke & Bieler LPMarketBeat report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
CNMD Q2 2026 Earnings: EPS Tops Estimates by 21.8% Despite Modest Stock Pullback - Dividend Increase Stockshttps://www.dars.gov.et/ report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 2d ago
The top 5 analyst questions from CONMED’s Q3 earnings callCONMED’s third quarter reflected stability in its core business, with year-over-year sales holding flat and revenue meeting Wall Street’s expectations. Management attributed the quarter’s results to solid execution in bo
RISK WATCHYahoo • 3d ago
CONMED (CNMD) Shares Dropped, So What Is Going On?CONMED (CNMD) has investors’ attention after third quarter results showed sales of US$335.56 million, roughly flat year on year, while net income increased to US$19.8 million and earnings guidance for 2026 was narrowed.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CNMD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CNMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.85%📐 WEDGE COMPRESSION COIL
2026-11-03O $45.72H $46.59L $44.29C $46.59VOL 404.1K
RES: $49.33SUP: $43.90SMA50: $46.82SMA200: $41.44
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CNMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
22.2%/yr Implied 5Y Growth
vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CNMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CNMD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CNMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNMD)
Health Care Rank #149 of 1015
⚔️ CBLL vs CNMD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CNMD vs. CBLL, TMDX, INMD, AXGN)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, CONMED Corporation (CNMD) ranks #149 by composite RQD confidence (62/100, grade C) and #321 by equity capitalization ($1.32B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. CNMD currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CNMD
ACTIVE
CONMED Corporation | C | 62/100 | 28.9x | 54.6% | 7.8% | +5.19% | $1.32B | Benchmark Subject |
| CBLL CeriBell Inc. | D- | 43/100 | — | 87.9% | -35.0% | +1.43% | $1.02B | /cbll-vs-cnmd → |
| TMDX TransMedics Group Inc. | C- | 61/100 | 12.2x | 59.9% | 18.1% | +1.03% | $2.29B | /tmdx-vs-cnmd → |
| INMD InMode Ltd. | D+ | 57/100 | — | 78.5% | 17.7% | +3.63% | $759.9M | /inmd-vs-cnmd → |
| AXGN Axogen Inc. | D+ | 53/100 | — | 74.3% | -2.6% | +0.97% | $2.95B | /axgn-vs-cnmd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000816956 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), CONMED Corporation (CNMD) reported GAAP revenue of $1.37B (+5.2% vs. FY2024 revenue of $1.31B , and +10.4% cumulative change since FY2023) , GAAP net income of $47.1M, operating cash flow of $170.7M, and free cash flow of $150.9M (-2.0% YoY). On the balance sheet, CNMD closed FY2025 with $2.33B in total assets against $0 in total debt (Altman Z-Score: 1.91, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.37B | $47.1M | $170.7M | $150.9M | $2.33B | — |
| FY2024 (FY) | 2024-12-31 | $1.31B | $132.4M | $167.0M | $153.9M | $2.31B | — |
| FY2023 (FY) | 2023-12-31 | $1.24B | $64.5M | $125.3M | $125.3M | — | — |
3. CNMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CNMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, CONMED Corporation (NYSE: CNMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $46.59 (+5.19% 1D, market cap $1.32B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, CNMD ranks #149 in composite RQD confidence.
How does CNMD compare to CBLL and TMDX in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CNMD carries a Roarable C (62/100 RQD), trailing P/E of 28.9x, gross margin of 54.6%, and ROIC of 7.8%. By comparison, CBLL (CeriBell Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and TMDX (TransMedics Group Inc.) posts a C- grade (61/100 RQD, P/E 12.2x, ROIC 18.1%, cap $2.29B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CNMD?
Per CNMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000816956), CONMED Corporation generated $1.37B in revenue (+5.2% YoY), $47.1M in net income, and $150.9M in free cash flow against $2.33B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CNMD trading relative to its 50-day, 200-day, and 52-week technical levels?
CNMD last traded at $46.59 (+5.19% on volume of 444,288 shares), positioning the stock -0.49% below its 50-day simple moving average ($46.82) and +12.43% above its 200-day simple moving average ($41.44). Across its 52-week range of $31.44 to $53.66, CNMD sits at the 68.2% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.4% ($42.68 to $50.50).
ROARABLE RATING BRIEF • RQD 62/100 (C)
✓ SEC XBRL & RQD VERIFIED
CNMD — CONMED Corporation: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
CONMED Corporation (CNMD) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $46.59 (+5.19% 1D, market capitalization $1.32B).
- Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 7.8%, gross margin of 54.6%, operating margin of 7.5%, and free cash flow yield of 11.07%.
- Whale 13F & Options Flow (7/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (13/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.91, Piotroski F-Score of 7/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
CONMED Corporation (CNMD) is listed on the NYSE in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Gross margin of 54.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CONMED Corporation (CNMD) reported $1.37B in annual revenue (up from $1.31B in FY2024, +5.2% YoY) and $47.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.24B revenue, $64.5M net income) through FY2025, CNMD scaled operating cash flow to $170.7M and free cash flow to $150.9M, backed by $2.33B in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C • RQD 62/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 11.07% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $31.44 – $53.66 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 28.9x trailing P/E and 11.4x EV/EBITDA against 7.5% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The source data therefore contains no upstream or downstream dependency mapping, no sector correlation data beyond the sector and industry labels, and no identified 2nd-order bottlenecks. Investors should treat supply-chain exposure as unverified from this dataset.
- Key Question #1: Can CNMD sustain or expand its 7.5% operating margin and 7.8% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $1.37B and free cash flow of $150.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is CNMD's 26.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
CNMD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for CONMED Corporation (CNMD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 21h ago
Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings Yahoo Finance report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
CONMED Corporation Stock 12‑Month Price Target Raised to $46.83, Implies 2% Upside TradingView report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
CONMED Corporation 2026 Q3 - Results - Earnings Call Presentation (NYSE:CNMD) 2026-11-01 Seeking Alpha report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
CONMED (NYSE:CNMD) - Stock Analysis Simply Wall St report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
CONMED Corporation (CNMD) Stock Forecasts Yahoo Finance report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Sales fell 0.7%, but grew 6.7% after currency shifts and exited product lines were excluded. Stock Titan report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
CONMED Corporation $CNMD Stake Reduced by Cooke & Bieler LP MarketBeat report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
CNMD Q2 2026 Earnings: EPS Tops Estimates by 21.8% Despite Modest Stock Pullback - Dividend Increase Stocks https://www.dars.gov.et/ report covering CONMED Corporation (CNMD) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CNMD Bull vs. Bear Conversation Board — What's Your Call at $46.59?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNMD 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $52.71 (+19.0%)
📌 Pinned Debate Free cash flow yield of 11.07% and a Piotroski F-Score of 7/9 indicate strong cash generation relative to the market price.
Don't sleep on CNMD's setup in Health Care. Free cash flow yield of 11.07% and a Piotroski F-Score of 7/9 indicate strong cash generation relative to the market price.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (62/100) backs up the fundamental quality.
RetailWhale_TX 🐂 BULL
@MeanReversion_88 Shorting a 7/20 institutional whale-flow stock at $44.29 is dangerous when funds are rotating into Health Care.
ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH
🎯 Target: $36.76 (-17.0%)
Spot @ $44.29 Net income fell from $132.4M in FY 2024 to $47.1M in FY 2025 while trailing P/E remains elevated at 28.9.
I respect the product at CONMED Corporation, but the stock at $44.29 is a different story. Net income fell from $132.4M in FY 2024 to $47.1M in FY 2025 while trailing P/E remains elevated at 28.9.. FCF yield is 11.07% and RQD sits at 62/100 (C) — why pay up here when you can wait for next quarter's numbers?